University of Wollongong

Research Online
Faculty of Science, Medicine and Health Papers: Part B

Faculty of Science, Medicine and Health

January 2020

Epithelial-to-mesenchymal transition and its association with PD-L1 and
CD8 in thyroid cancer
Marra Aghajani
Tao Yang
Ulf Schmitz
Alexander James
Charles McCafferty

See next page for additional authors

Follow this and additional works at: https://ro.uow.edu.au/smhpapers1

Publication Details Citation
Aghajani, M., Yang, T., Schmitz, U., James, A., McCafferty, C., De Souza, P., Niles, N., & Roberts, T. (2020).
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. Faculty of
Science, Medicine and Health - Papers: Part B. Retrieved from https://ro.uow.edu.au/smhpapers1/1766

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in
thyroid cancer
Abstract
2020 The authors Published by Bioscientifica Ltd. Programmed cell death-ligand 1 (PD-L1) has recently
been shown to play a role in the regulation of epithelial-to-mesenchymal transition (EMT); however, the
relationship between PD-L1 expression, EMT and the inflammatory tumour microenvironment has yet to
be investigated in thyroid cancer. To address this issue, we examined the expression of CD8, PD-L1 and
the EMT markers E-cadherin and vimentin in a cohort of 74 papillary thyroid cancer (PTC) patients and
investigated the association of these with clinicopathologic characteristics and disease-free survival
(DFS). The relationship between PD-L1 and EMT was further examined in three thyroid cancer cell lines
via Western blot and live cell imaging. In order to expand our in vitro findings, the normalised gene
expression profiles of 516 thyroid cancer patients were retrieved and analysed from The Cancer Genome
Atlas (TCGA). PD-L1 positivity was significantly higher in PTC patients exhibiting a mesenchymal
phenotype (P = 0.012). Kaplan-Meier analysis revealed that PD-L1 (P = 0.045), CD8 (P = 0.038) and EMT
status (P = 0.038) were all significant predictors for DFS. Sub-analysis confirmed that the poorest DFS
was evident in PD-L1 positive patients with EMT features and negative CD8 expression (P < 0.0001). IFN-γ
treatment induced upregulation of PD-L1 and significantly promoted an EMT phenotype in two thyroid
cancer cell lines. Our findings suggest that PD-L1 signalling may play a role in stimulating EMT in thyroid
cancer. EMT, CD8 and PD-L1 expression may serve as valuable predictive biomarkers in patients with
PTC.
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Abstract
Programmed cell death-ligand 1 (PD-L1) has recently been shown to play a role in the
regulation of epithelial-to-mesenchymal transition (EMT); however, the relationship
between PD-L1 expression, EMT and the inflammatory tumour microenvironment has yet
to be investigated in thyroid cancer. To address this issue, we examined the expression of
CD8, PD-L1 and the EMT markers E-cadherin and vimentin in a cohort of 74 papillary thyroid
cancer (PTC) patients and investigated the association of these with clinicopathologic
characteristics and disease-free survival (DFS). The relationship between PD-L1 and EMT
was further examined in three thyroid cancer cell lines via Western blot and live cell
imaging. In order to expand our in vitro findings, the normalised gene expression profiles
of 516 thyroid cancer patients were retrieved and analysed from The Cancer Genome Atlas
(TCGA). PD-L1 positivity was significantly higher in PTC patients exhibiting a mesenchymal
phenotype (P = 0.012). Kaplan–Meier analysis revealed that PD-L1 (P = 0.045), CD8 (P = 0.038)
and EMT status (P = 0.038) were all significant predictors for DFS. Sub-analysis confirmed
that the poorest DFS was evident in PD-L1 positive patients with EMT features and
negative CD8 expression (P < 0.0001). IFN-γ treatment induced upregulation of PD-L1 and
significantly promoted an EMT phenotype in two thyroid cancer cell lines. Our findings
suggest that PD-L1 signalling may play a role in stimulating EMT in thyroid cancer. EMT, CD8
and PD-L1 expression may serve as valuable predictive biomarkers in patients with PTC.
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Introduction
The incidence rate of thyroid cancer has risen rapidly
over the last 4 decades (1). Differentiated thyroid cancers
(DTCs), derived from thyroid follicular cells, are the most
common subtype, accounting for over 90% of all newly
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diagnosed cases (2). The mounting incidence rate has
been attributed to improvements in access to health care
systems, increased incidental detection on imaging, more
widespread diagnostic testing of asymptomatic thyroid
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nodules, a rise in the volume and extent of surgery, and
modifications in pathology practices (3). However, recent
evidence supports a true increase in the occurrence of the
disease, possibly due to hormonal, environmental, and
genetic factors (4).
Whilst the majority of patients with DTC have
a favourable prognosis, 1–9% present with distant
metastasis at the time of initial diagnosis (5), and 7–23%
show distant metastasis during follow-up (6). Moreover,
25–50% of patients with locally advanced or metastatic
DTC become refractory to radioactive iodine (RAI)
therapy (7). Inoperable or RAI-refractory metastatic DTC
is associated with a 10-year survival of only 10%, and
restricted treatment options are currently available (7).
Following initial surgery, the american joint committee
on cancer (AJCC)/international union against cancer
(UICC) tumour node metastasis (TNM) staging system
is commonly implemented to predict disease-specific
mortality and is consulted when tailoring decisions
concerning postoperative adjunctive therapy. Whilst the
AJCC/UICC TNM staging provides important information
regarding mortality, it inaccurately predicts the risk of
persistent or recurrent disease following initial therapy (8).
Research is needed to establish whether the inclusion of
additional variables can enhance the predictive capabilities
of the current AJCC/UICC TNM staging system.
Programmed cell death protein 1 (PD‐1), an
inhibitory costimulatory molecule expressed on activated
T, B, and NK cells, plays a critical role in the regulation of
peripheral tolerance (9). Two PD‐1 binding ligands have
been identified; programmed death ligand 1 (PD‐L1) and
programmed death ligand 2 (PD‐L2) (9). PD‐L1 is expressed
by various human tumours and, following binding to
PD-1, has been shown to induce potent inhibition of
T-cell mediated anti-tumoural immunity (10). Elevated
PD‐L1 levels have been associated with a poor prognosis
in multiple cancer types (11). We have completed a
meta-analysis confirming that non-medullary thyroid
cancer patients expressing PD-L1 were three times more
likely to have a poorer disease-free survival (DFS) than
patients who did not have positive PD-L1 expression (12).
Immunotherapies targeting the PD-1/PD-L1 pathway
have demonstrated durable responses in selected patients
across multiple cancer types, including thyroid cancer (13,
14). However, optimal biomarkers predictive of patient
response are currently lacking (15).
Epithelial-to-mesenchymal transition (EMT) is a
biological process which plays a central role in cancer
progression, metastasis, and drug resistance. During
EMT, a polarised epithelial cell, which interacts with
https://ec.bioscientifica.com
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the basement membrane, adopts a mesenchymal cell
phenotype, which is associated with an enhanced
migratory capacity and invasiveness, greater resistance
to apoptosis, and markedly increased production of
extracellular matrix components (16). Throughout this
process, epithelial markers including epithelial cell
adhesion molecule (EpCAM) and E-cadherin are downregulated, whilst the mesenchymal markers vimentin and
N-cadherin increase in expression. Vimentin has gained
much importance as a canonical marker of EMT, with
its overexpression associated with accelerated tumour
growth, invasion, and poor prognosis (17). E-cadherin is a
member of the cadherin family that is primarily detected
in epithelial cells. Decreased E-cadherin expression
reduces cell-cell contact and promotes EMT induction,
resulting in tumour motility (17). Activation of EMT has
recently been shown to play a key role in thyroid cancer
progression, namely by promoting capsular invasion,
extrathyroidal extension and both local and distant
metastasis (18). Therefore, E-cadherin and vimentin are
promising biomarkers associated with invasiveness, poor
differentiation and malignant phenotype.
A bidirectional relationship has recently been
established between EMT and PD-L1 expression (19, 20,
21, 22). Preliminary observations point to a potential role
of EMT markers as predictors of patient response to PD-1/
PD-L1 axis therapies (21). Cancers containing a high level
of pre-existing T cell infiltrate and a pro-inflammatory
IFN signature, referred to as ‘hot’ tumours, have also been
shown to more readily respond to PD-1/PD-L1 directed
immunotherapies blockade (23). However, the relationship
between T cell infiltrate, PD-L1 and EMT status, and their
influence on the progression and metastasis of human
thyroid cancer, has yet to be investigated. To address
this issue, we examined the expression of CD8, PD-L1
and the EMT markers E-cadherin and vimentin in a
cohort of PTC patients and investigated the association
of these with clinicopathologic characteristics and DFS.
The relationship between these markers were further
investigated in three thyroid cancer cell lines via Western
blot and IncuCyte live cell imaging.

Materials and methods
Patient characteristics
Ethics approval was obtained from the south west
Sydney Local Health District Human Research Ethics
Committee via the Centre for Oncology Education and
Research Translation (CONCERT) Biobank, Australia/
This work is licensed under a Creative Commons
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TCRC/3/02-03-2015 (24). In this study, the archived
paraffin embedded tissues from 74 PTC patients that
underwent surgical resection within the south west
Sydney Local Health District from 2006 to 2015 were
obtained. Patient demographics and clinicopathologic
parameters, including age, sex, tumour stage, tumour
size, capsular invasion, extrathyroidal extension,
lymphovascular invasion, multicentricity, presence of
concurrent lymphocytic thyroiditis and lymph node
metastasis, were acquired via retrospective medical record
review. Standard American Joint Committee on Cancer,
8th edition, tumour-node-metastases (TNM) scoring was
implemented for thyroid cancer staging. All patients were
followed up for survival status until October 2019.
DFS was defined as the period between completion
of primary treatment and detection of residual disease,
recurrent disease or death. This definition was adopted
from the 2015 American Thyroid Association (ATA)
Management Guidelines (25). An excellent response
(absence of persistent tumour) following initial therapy
was defined as negative imaging and either a low serum
thyroglobulin (Tg) during thyroid stimulating hormone
(TSH) suppression (Tg < 0.2 ng/mL) or following stimulation
(Tg < 1 ng/mL). A structural incomplete response was
defined as structural or functional evidence of disease with
any Tg level, whilst a biochemical incomplete response
was designated to patients with negative imaging and a
suppressed Tg ≥ 1 ng/mL or a stimulated Tg ≥ 10 ng/mL.
Patients that did not experience tumour recurrence were
censored at the last follow-up contact.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tissues were
collected from 74 patients with a confirmed diagnosis
of PTC and were used to construct tissue microarrays
(TMAs). Considering spatial heterogeneity, duplicate
tissue cores of 0.6 mm diameter were obtained from the
normal tissue, tumour centre and tumour periphery.
Tissue blocks were cut into 4-μm sections for analysis.
Sections were stained with anti-PD-L1 (clone SP263)
rabbit monoclonal primary antibody (Ventana Medical
Systems) on the Ventana BenchMark Ultra automated
staining platform using the OptiView Detection Kit.
The Leica Bond III Immuno-autostainer was used for
CD8 staining with the mouse anti-human CD8 clone
C8/144B, 1:100 (DAKO). TMAs were also stained with
the monoclonal mouse anti-human e-cadherin clone
NCH-38, 1:100 (DAKO) and monoclonal mouse antivimentin clone V9, 1:500 (DAKO).
https://ec.bioscientifica.com
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The scoring of vimentin and E-cadherin was based on
previously published methods (26, 27). Vimentin staining
was scored as follows: 0 = no expression, 1 = fragmented
membranous and/or weak to moderate expression,
2 = fragmented strong or fully membranous moderate
expression, and 3 = fully membranous strong expression.
A score of ≥2 was considered as positive vimentin
expression. The area intensity score method was used to
score E-cadherin, which incorporates both the staining
intensity and the number of positive cells. The intensity of
staining was scored as 0 = negative, 1 = weak, 2 = moderate,
and 3 = intense. The percentage of positively stained cells
was scored as follows; 0 = 0–5% positive cells, 1 = 6–25%
positive cells, 2= 26–50% positive cells, 3 = 51–75% positive
cells, and 4 = 75–100% positive cells. The two scores for the
intensity and the percentage of positive cells were then
multiplied to generate a final score ranging from 0 to 12.
E-cadherin expression was dichotomised as negative (score
of 0–6) and positive (score of 7–12) for outcome analyses.
Patients considered to be EMT positive were those that were
scored both vimentin ‘positive’ and E-cadherin ‘negative’.
PD-L1 expression was scored based on the percentage
of immunopositively stained cancer cells, with a score
of ≥1% considered positive PD-L1 staining. Scoring of
CD8 expression was performed as previously described
(28). Briefly, a quantitative score based on the percentage
of immunopositively stained cells among total cells was
given according to the following scale: 1 (<1% cells); 2
(1–10% cells); 3 (11–33% cells); 4 (34–66% cells) and 5
(67–100% cells). Staining intensity was then scored
as follows: 0 (none), 1+ (mild), 2+ (moderate), and 3+
(intense). Finally, Allred scores (ranging from 1 to 8) were
calculated by adding the percentage positivity scores and
the intensity scores for each of the sections. The median
value was used to separate the patient cohort into two
groups with either negative or positive CD8 expression.
Figure 1 provides representative cases of E-cadherin,
vimentin, PD-L1 and CD8 scoring. Two authors
(T Y and M A) blinded to tumour clinicopathological
characteristics and patient outcomes scored the slides,
with any discrepancies resolved by consensus.
Cell culture
The follicular thyroid cancer (FTC) and PTC cell lines
FTC-133 and K1 were cultured in DMEM: Ham’s F12 (1:1)
medium (Sigma-Aldrich) containing 2 mM glutamine
(Thermo Fisher) and 10% foetal bovine serum (FBS) (Thermo
Fisher). The anaplastic thyroid cancer (ATC) cell line 8505C
was cultured in EMEM (HBBS) medium supplemented with
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Downloaded from Bioscientifica.com at 11/17/2020 10:50:36PM
via free access

M J Aghajani et al.

EMT, PD-L1 and CD8 as thyroid
cancer biomarkers

9:10

1031

supplemented with phosphatase (sodium fluoride, sodium
molybdite, sodium pyrophosphate) and complete Mini,
EDTA-free protease inhibitors (Roche). 15–25 μg total
protein (depending on different proteins) were separated
by SDS-PAGE and then transferred to polyvinylidene
difluoride membranes (Roche). For each gel, the same
amount of protein was loaded per lane. Membranes were
then blocked in 5% non-fat milk in Tris-buffered salineTween for1 h. The immunoblotting was performed by
incubation at 4°C overnight with the following primary
antibodies: anti-PD-L1 antibody (13684) (Cell Signaling
Technology), anti-E-cadherin (ab15148) (Abcam), antivimentin (ab92547) (Abcam) and β-actin (Cell Signaling
Technology), which was used as an endogenous protein
for normalisation. Blots were then washed and incubated
with a 1:1000 dilution of anti-Rabbit IgG H&L (HRP)conjugated secondary (Cell Signaling Technology) or a
1:1000 dilution of anti-mouse IgG H&L (HRP)-conjugated
secondary (Cell Signaling Technology). Signals were
detected by enhanced chemiluminescence Plus reagents
(PerkinElmer) and images were captured using a Licor
Odyssey System. Signal quantification was obtained using
Image Studio Lite software (Version 5.2.5). All experiments
were performed in triplicate.
Dataset analysis
Figure 1
Representative staining of formalin-fixed paraffin-embedded (FFPE) tissues
from PTC patients. Negative (A) and positive (B) immunohistochemical (IHC)
staining pattern for E-cadherin expression. Negative (C) and positive (D) IHC
staining pattern for vimentin expression. Negative (E) and positive (F) IHC
staining pattern for PD-L1 expression. Negative (G) and positive (H) IHC
staining pattern for CD8+ expression. Images were taken at 5×
magnification (A) and 40× magnification (remaining images).

2 mM glutamine (ThermoFisher), 1% non-essential amino
acids (Sigma-Aldrich) and 10% FBS (Thermo Fisher). All
media were supplemented with penicillin-streptomycin
(Thermo Fisher) and all cells were incubated at 37°C in 5%
CO2. EMT was induced using recombinant human IFN-γ
(300-02) (10 ng/mL, Peprotech).
Live cell imaging assays were performed using the
IncuCyte® Live-Cell Analysis System (Essen BioScience, Ann
Arbor, MI, USA). Cells were imaged at 10× magnification at
37°C with 5% CO2. Images were acquired every 4 h for 48 h.
Western blot analysis
Western blotting was performed as described previously
(29). Briefly, cells were harvested and lysed in RIPA buffer
https://ec.bioscientifica.com
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Normalised gene expression profiles (RNA Seq V2 RSEM) of
516 PTC patients were retrieved from The Cancer Genome
Atlas (TCGA) via the Cancer Genomics Data Server
package (cgdsrv1.2.10; github.com/cBioPortal/cgdsr). The
EMT score was computed using the mean expression of
mesenchymal genes (ZEB1, ZEB2, SNAI1, SNAI2, TWIST1,
TWIST2, VIM, FOXC2, SOX10, FN1, MMP2, MMP3)
minus the mean expression of epithelial genes (CDH1,
CLDN3, CLDN4, CLDN7, DSP), as previously described by
Alsuliman et al. (22). The IFN gene signature was based
on the 18-gene tumour inflammation signature reported
by Ayers et al. (30), which included the following genes;
PSMB10, HLA-DQA1, HLA-DRB1, CMKLR1, HLA-E, NKG7,
CD8A, CCL5, CXCL9, CD27, CXCR6, IDO1, STAT1,
TIGIT, LAG3, CD274, PDCD1LG2, CD276. Correlation
coefficients of PD-L1 expression and EMT score, or mean
expression of the IFN signature genes and EMT score were
computed using Pearson correlation. Survival analyses
(Kaplan-Meier) based on DFS were performed using
the survival package (v2.44 1.1; github.com/therneau/
survival). The heatmap was generated using the Complex
Heatmap package (v2.1.0) (31). All data analyses have
been performed using R version 3.6.0.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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Statistical analysis

Table 1

Correlations were analysed using the Pearson’s chisquared test and Fisher’s exact test. The student t-test
with Welch’s correction was implemented to compare
differences between control and treated cell lines.
Two-sided P values < 0.05 was considered statistically
significant. Results are representative of three independent
experiments and are expressed as mean ± s.d. Survival
curves were plotted using the Kaplan-Meier method and
compared using the log-rank test. A Cox regression model
was used to perform multivariate analyses. All statistical
analyses were completed using GraphPad Prism v.7.0d
and SPSS software (version 22).

Patient characteristics

Results
Patient characteristics
The main characteristics of the 74 PTC patients included
in the study are detailed in Table 1. The median age of the
patients at diagnosis was 51 years. The majority of patients
were female (65/74) or had a tumour size less than 2 cm
(59/74). Only 10 patients in the cohort were diagnosed
with TNM stage III/IV disease. This was expected as the
majority of thyroid cancers are identified and diagnosed
at an early stage.

PD-L1 expression is associated with EMT status in
papillary thyroid cancer patients
The expression of E-cadherin, vimentin, PD-L1 and
CD8were all assessed via IHC staining of TMAs. Of the
74 cases, 16 were scored positive for E-cadherin whilst 51
patients expressed positive vimentin staining. Forty-five
cases were considered EMT positive (E-cadherin negative
and vimentin positive). Positive PD-L1 expression was
observed in 49 patients. PD-L1 positivity was significantly
higher in PTC patients displaying a mesenchymal
phenotype (Fig. 2; P = 0.012), as determined by negative
E-cadherin and positive vimentin expression. Elevated
CD8 levels were identified in 39 patients.
PD-L1, EMT and CD8 are predictive for DFS in
PTC patients
EMT status and the expression of PD-L1, E-cadherin,
vimentin, and the presence of CD8T cells were not
significantly associated with any clinicopathological
characteristics (Supplementary Tables 1, 2, 3, 4 and 5,
https://ec.bioscientifica.com
https://doi.org/10.1530/EC-20-0268

© 2020 The authors
Published by Bioscientifica Ltd

1032

9:10

EMT, PD-L1 and CD8 as thyroid
cancer biomarkers

Clinical summary of patients.
Number of patients (n = 74)

Age
Median (range)
<55
≥55
Sex
Male
Female
TNM stage
I/II
III/IV
Tumour size
<2 cm
≥2 cm
Multifocality
Present
Absent
Extrathyroidal extension
Present
Absent
Lymphovascular invasion
Present
Absent
Lymph node metastases
Present
Absent
Concurrent Hashimoto’s thyroiditis
Present
Absent

51 (24–80)
44
30
9
65
64
10
59
15
14
60
15
59
6
68
14
60
30
44

see section on supplementary materials given at the end
of this article). Interestingly, all six PTC patients which
experienced lymphovascular invasion were EMT positive
(i.e. displayed a mesenchymal phenotype); however, this
did not reach statistical significance (Table 2; P = 0.075),
likely due to the small number of patients in this
sub-group.
At the time of analysis, the median duration of
follow-up of the 74 cases was 45.5 months (range:

Figure 2
PD-L1 expression is associated with mesenchymal phenotype. Cases were
separated in PD-L1 negative (blue) (n = 25) and positive (red) (n = 49)
subgroups. These were then assessed for epithelial vs mesenchymal
state. By Fisher’s exact test there was a significant positive association
between PD-L1 expression and a mesenchymal phenotype.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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Univariate and multivariate analysis of clinicopathologic factors associated with DFS in PTC cases.

Patient characteristics

Age
<55 vs
≥55
Sex
Male vs
Female
TNM stage
I vs II vs
III vs IV
Tumour size
<2 cm vs
≥2 cm
Multifocality
Present vs
Absent
Extrathyroidal extension
Present vs
Absent
Lymphovascular invasion
Present vs
Absent
Lymph node metastases
Present vs
Absent
Concurrent Hashimoto’s thyroiditis
Present vs
Absent
PD-L1
Negative vs
Positive
CD8
Negative vs
Positive
EMT status
E-cadneg/Vimneg vs
E-cadneg/Vimpos vs
E-cadpos/Vimneg vs
E-cadpos/Vimpos

Univariate analysis
P value

95% CI

P value

0.736

1.986

0.546–7.226

0.298

0.362

1.258

0.281–5.643

0.764

0.061

1.043

0.488–2.231

0.913

0.327

0.956

0.253–3.608

0.947

0.128

2.340

0.604–9.063

0.219

0.154

1.050

0.260–4.241

0.945

0.004*

2.826

0.416–19.188

0.288

0.006*

1.819

0.441–7.515

0.408

0.424

0.900

0.242–3.346

0.875

0.048*

3.053

0.599–15.552

0.179

0.028*

0.536

0.135–2.130

0.376

0.026*

3.132

1.102–8.897

0.032*

2–129 months). A total of 16 cases experienced tumour
persistence and/or recurrence. Univariate analysis
revealed that e-cadherin was not a significant predictor of
DFS in our cohort (Fig. 3A; P = 0.384); however, a positive
vimentin score was significantly associated with a reduced
DFS (Fig. 3B; P = 0.003). A high density of tumoural CD8T
cells was a favourable biomarker predictive of improved
DFS (Table 2, Fig. 3C; P = 0.028), whilst positive PD-L1
expression was significantly associated with an increased
incidence of persistent or recurrent disease (Table 2, Fig.
3D; P = 0.048. The presence of lymph node metastases
(Table 2; P = 0.006) and lymphovascular invasion
(P = 0.004) were also significant predictors of DFS on
univariate analysis in our cohort.

https://ec.bioscientifica.com
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Subgroup analysis
Based on EMT marker staining, we categorised all 74
tissue sections into four subgroups; (i) E-cadherinnegative/
vimentinnegative (n = 13), (ii) E-cadherinnegative/vimentinpositive
(n = 45), (iii) E-cadherinpositive/vimentinnegative (n = 10), and
(iv) E-cadherinpositive/vimentinpositive (n =6 ). Patients that
were E-cadherinnegative/vimentinpositive and E-cadherinpositive/
vimentinpositive experienced the shortest DFS compared to
the other two subgroups (Fig. 4A; P = 0.026). The patients
were then allocated one of two major subgroups; (i) an
EMT positive subgroup (n = 45), including patients with
a negative E-cadherin and positive vimentin scores, or
(ii) an EMT negative subgroup (n = 29), which included
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Figure 3
Vimentin, CD8+ and PD-L1 were all predictive for
DFS in the PTC cohort. Kaplan-Meier curves for
DFS of PTC patients with positive and negative
E-cadherin expression (E-cadpos (n = 16) vs E-cadneg
(n = 58); P = 0.384) (A), vimentin expression
(Vimentinpos (n = 51) vs Vimentinneg (n = 23);
P = 0.003) (B), CD8+ density (CD8pos (n = 39) vs.
CD8neg (n = 35); P = 0.028) (C) and positive or
negative PD-L1 expression (PD-L1pos (n = 49) vs.
PD-L1neg (n = 25); P = 0.048) (D). P-values were
calculated by the log-rank test.

all other patients. EMT positive cases had a significantly
higher incidence of recurrence compared to EMT negative
patients (P = 0.021). On multivariate analyses, EMT status
remained as the only significant independent predictor
for DFS (Table 2; P = 0.032).
Further sub-analysis was performed to assess the
relationship between PD-L1, EMT and CD8 expression,

and prognosis. Patients that were scored both EMT and
PD-L1 negative (n = 39) had the longest DFS compared
with all other patients (n = 34) (Fig. 4B; P = 0.003).
Moreover, PD-L1negative/EMTnegative/CD8positive patients
(n = 7) experienced no recurrent or persistent disease,
whilst those considered PD-L1positive/EMTpositive/CD8negative
(n = 15) experienced the shortest DFS (Fig. 4C; P < 0.0001).

Figure 4
Patients positive for EMT and PD-L1 expression,
and negative for CD8+ T-cell expression
experienced the worst DFS on subgroup analysis.
Kaplan-Meier curves for DFS of PTC patients with
positive and negative E-cadherin and Vimentin
expression (E-cadneg/Vimneg (n = 13) vs
E-cadpos/Vimneg (n = 10) vs E-cadneg/Vimpos (n = 45)
vs E-cadpos/Vimpos (n = 6); P = 0.026) (A), positive
and negative EMT status and PD-L1 expression
(EMTneg/PD-L1neg (n = 39) vs EMTneg/PD-L1pos and
EMTpos/PD-L1neg and EMTpos/PD-L1pos (n = 35);
P = 0.003) (B), and positive and negative EMT
status, PD-L1 expression and CD8 density
(EMTpos/PD-L1pos/CD8neg (n = 15) vs
EMTneg/PD-L1neg/CD8pos (n = 7) vs Other (n = 52);
P < 0.0001) (C). P values were calculated by the
log-rank test.
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Clinical datasets and mRNA expression profiles
In order to expand our IHC findings, the normalised
gene expression profiles of 516 thyroid cancer patients
were retrieved from TCGA. The profiles were comprised
of 399 PTCs, 107 FTCs, 1 patient with PDTC, 1 patient
with well-differentiated thyroid cancer, and 8 thyroid
cancers that were not otherwise specified. An EMT score
of each thyroid cancer sample was calculated using the
mean expression of mesenchymal genes minus the mean
expression of epithelial genes (additional detail in the
‘Materials and methods’ section). This was then correlated
with PD-L1 gene expression, or the mean expression of
IFN signature genes (Fig. 5F). We observed a moderate
positive linear relationship between EMT status and
PD-L1 expression (Fig. 5A; r = 0.481171) and an IFN gene
signature (Fig. 5B; r = 0.360384). When considering only
PTCs (n = 399), the correlation coefficient between EMT
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status and PD-L1 strengthened (Fig. 5C; r = 0.502354).
Moreover, in the subset of PTCs which experienced disease
recurrence/progression (n = 40), a strong correlation was
identified between positive PD-L1 and EMT expression
(Fig. 5D; r = 0.623002). This was also observed when
patients of all subtypes which experienced disease
recurrence/progression (n = 49) were included (Fig. 5E;
r = 0.656826). These results align with the findings from
our patient cohort, in which we observed a significant
association between PD-L1 expression and EMT status.
In the TCGA PTC patient cohort, a higher EMT and
mesenchymal genes score were both significantly
associated with poorer DFS outcomes (P = 0.0027 (Fig.
5G) and P = 0.0085 (Fig. 5H), respectively). Similarly, the
EMT status remained the only significant predictor for
DFS on multivariate analysis in our cohort. Together,
these findings confirm a significant association between
PD-L1 and EMT status in PTC.

Figure 5
Correlation of PD-L1 expression, EMT and an IFN gene signature in thyroid cancer using TCGA gene expression dataset. Gene expression dataset from
the TCGA thyroid cancer samples (total of 516 patients) showing the correlation between PD-L1 expression with EMT score (r = 0.481171) (A), correlation
between IFN score and EMT score (r = 0.360384) (B). Correlation between PD-L1 expression and EMT score in PTC patients only (n = 399) (r = 0.502354)
(C). Correlation between PD-L1 expression and EMT score in PTC patients experiencing disease recurrence/progression (n = 40) (r = 0.623002) (D).
Correlation between PD-L1 expression and EMT score in all patients experiencing disease recurrence/progression (n = 49) (r = 0.656826) (E). Heat map
showing mRNA expression level of epithelial genes, mesenchymal genes, and IFN-γ related genes (F). Kaplan-Meier curves for DFS of TCGA thyroid cancer
patients with positive and negative EMT score (P = 0.0027) (G) and positive and negative mesenchymal gene expression (P = 0.0085) (H).
https://ec.bioscientifica.com
https://doi.org/10.1530/EC-20-0268

© 2020 The authors
Published by Bioscientifica Ltd

This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Downloaded from Bioscientifica.com at 11/17/2020 10:50:36PM
via free access

M J Aghajani et al.

IFN-γ induced PD-L1 expression and EMT in vitro
In order to investigate the relationship between PD-L1
expression and EMT status, PD-L1 expression was induced
via IFN-γ treatment in three thyroid cancer cell lines (K1;
papillary thyroid cancer, FTC-133; follicular thyroid cancer,
8505C; anaplastic thyroid cancer). Following treatment,
changes in PD-L1, E-cadherin and vimentin protein
expression were assessed via Western blot. Treatment
with 10 ng/mL of IFN-γ for 48 h significantly increased
the expression of PD-L1 in all cell lines (Fig. 6A, B and C).
Upregulation in PD-L1 occurred alongside a significant
decrease in E-cadherin and increase in vimentin expression
in two of the thyroid cancer cell lines examined (Fig. 6A
and B). In the 8505C and K1 cell lines, the morphological
appearance changed from cobblestone tightly arranged
cells (epithelial like) to spindle -shaped cells that were
widely distributed (mesenchymal like) (Fig. 6D and E).
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These findings were not observed in the FTC cell line. The
FTC-133 cell line, which was originally obtained from a
lymph node metastasis of a patient with FTC, demonstrates
a spindle-shaped morphology at baseline (Fig. 6F) as well
as strong levels of vimentin expression in untreated cells
(Fig. 6C). This cell line may therefore possess a more
mesenchymal phenotype constitutively and may not be
expected to undergo the same morphological changes
observed in 8505C and K1 cells. Collectively, these results
suggest that IFN-γ treatment promoted PD-L1 expression
and induced EMT characteristics in K1 and 8505C cells.

Discussion
The significant role of the PD-1/PD-L1 pathway in
suppressing the anti-tumour immune response has been
well established (32). PD-1/PD-L1 pathway proteins are

Figure 6
IFN-γ treatment upregulated PD-L1 expression and induced EMT in thyroid cancer cell lines. PD-L1, E-cadherin and vimentin expression following 48-h
10 ng/mL IFN-γ treatment in 8505C (A), K1 (B) and FTC-133 (C) thyroid cancer cells lines. A morphological change indicative of EMT was observed in the 8505C
(D) and K1 (E) cell lines. This was not evident in the FTC (F) cell line which demonstrated a more mesenchymal morphology at baseline. Quantification of
Western blotting data (n = 3) was performed via Licor Odyssey, which showed a significant reduction in PD-L1 expression in all cell lines assessed. P values
were calculated by the student t test with Welch’s correction. *P < 0.05, **P < 0.01. All experiments were performed in triplicate. The bars in each column
show the mean, and the error bars demonstrate the s.d. from three independent experiments. The scatter dot plots represent the individual data points.
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highly expressed in patients with more aggressive thyroid
cancer variants. Whilst stage I PTCs exhibited low levels
of cytoplasmic PD-L1 staining assessed via IHC, markedly
increased expression has been observed in stage III and
IV PTC cases (33). A significant increase in membrane
PD-L1 expression was correlated with a higher risk of
aggressive disease, distant metastasis and death in stage IV
patients (33). We have recently published a meta-analysis
confirming that elevated PD-L1 status is a prognostic
indicator for reduced DFS in patients with non-medullary
thyroid carcinoma (12). Patients with upregulated PD-L1
were up to three times as likely to have a poorer prognosis
than those with negative PD-L1 expression. These
findings suggest that PD-L1 may provide clinicians with
a prognostic biomarker capable of identifying thyroid
cancer patients with aggressive disease at an earlier stage
and may be useful in the selection of individuals that
would derive durable clinical benefit from anti-PD-1/
PD-L1 immunotherapy.
Immunotherapies targeting the PD-1/PD-L1 axis
have exhibited durable responses and improved survival
rates across numerous cancer types (34). However, a large
fraction of patients still fail to benefit from treatment,
with response rates of less than 20% often reported (35).
The evaluation of PD‐L1 expression via IHC is currently
the most widely implemented tool used in the selection
of patients for treatment with PD-1/PD-L1 directed
immunotherapies (36). Several concerns regarding its
use have been recognised, including inconsistencies in
expression between archival versus fresh biopsy, inter- and
intra-tumoural heterogeneity and a lack of standardisation
between assays (37). Moreover, response rates of 11 to
20% have been reported in patients with negative PD-L1
expression, highlighting its limited use as an independent
biomarker for immunotherapy response (38).
The incorporation of additional predictive markers
may improve patient selection and prevent avoidable
toxicities and costs in individuals unlikely to benefit
from treatment. EMT status has recently been identified
as a potential candidate marker that can be implemented
alongside PD-L1 to predict patient outcomes and
response to therapy (39). Positive PD-L1 expression
was significantly associated with the presence of EMT
in the tumour tissues from 50 patients diagnosed with
head and neck squamous cell carcinoma (19). Overall
survival was significantly reduced in PD-L1 positive
patients also demonstrating EMT features; these findings
were confirmed in an independent validation cohort
and two public databases. Similar findings have been
observed in non-small-cell lung carcinoma (NSCLC) (40),
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thymic carcinoma (41), extrahepatic cholangiocarcinoma
(42), oral squamous cell carcinoma (43), oesophageal
squamous cell carcinoma (OSCC) (44) and hepatocellular
carcinoma (45). We have also determined that PTC patients
exhibiting a mesenchymal phenotype were more likely
to co-express tumoural PD-L1 (P = 0.012). These findings
were confirmed in the TCGA dataset analysis, in which a
moderate positive linear relationship between EMT status
and PD-L1 expression (r = 0.481171) as well as an IFN gene
signature (r = 0.360384) was observed. In the subset of
PTCs which experienced disease recurrence/progression
(n = 40), a stronger correlation was identified between
positive PD-L1 and EMT expression (r = 0.623002); this
was further strengthened when patients of all subtypes
were included in the analysis (n = 49) (r = 0.656826).
PD-L1, EMT status and CD8T cell expression were all
not significantly associated with any clinicopathological
characteristics; this may be a consequence of the relatively
small cohort size, and the limited number of patients
presenting with metastatic disease. EMT status remained
the only significant predictor of DFS on multivariate
analysis (P = 0.032); these findings were also reflected in
the TCGA PTC patient cohort, in which a higher EMT
and mesenchymal genes score were both significantly
associated with a poorer DFS (P = 0.0027 and P = 0.0085,
respectively).
The mechanisms by which EMT regulates components
of the tumour immune microenvironment, including
the PD-1/PD-L1 pathway, have recently been elucidated.
A meta-analysis revealed that PD-L1 gene expression
was co-amplified along with the EMT associated genes
MYC, SOX2, N-cadherin and SNAI1 in the endometrial
and ovarian cancer datasets from TCGA (46). The gene
promoter region of PD‐L1 contains a binding site for ZEB1,
a transcription factor which contributes to cancer stemness
and tumourigenesis (47, 48). siRNA-mediated ZEB1
knockdown suppressed PD-L1 levels whilst promoting
E-cadherin expression in OSCC (49). Cases expressing
high PD‐L1 at the invasive front also had significantly
greater tumour invasion, EMT, and less CD8 lymphocyte
infiltration. EMT-converted OSCC cell lines expressing
high levels of PD-L1 at both protein and mRNA levels were
capable of inducing T‐cell apoptosis to a greater extent
when compared to the original epithelial type tumour
cells (44). In breast cancer cell lines, EMT-mediated PD-L1
upregulation occurred in parallel with the up- and downregulation of the stem-cell-related CD44 and CD24 surface
markers, respectively; this was also accompanied by a
morphological change from tightly arranged epitheliallike cells to widely distributed mesenchymal-like cells
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(22). A molecular relationship between EMT and CD8 T
cells was demonstrated by Chen et al., in which ZEB1, an
EMT activator and transcriptional repressor of miR-200 (a
cell-autonomous suppressor of EMT and metastasis), was
shown to relieve miR-200 repression of PD-L1 on tumour
cells, resulting in CD8 T-cell immunosuppression and
metastasis. These findings were further supported by a
strong correlation between EMT score, levels of miR-200
and PD-L1 expression in numerous human lung cancer
datasets. Preclinical models of melanoma, pancreatic and
breast cancer have also demonstrated that the expression
of certain transcription factors, such as Snail or Neu, can
induce EMT and are associated with the activation of
immunosuppressive cytokines and T-cell resistance. In our
study, the prognostic capabilities of EMT were markedly
enhanced when used in conjunction with PD-L1 and
CD8 expression (P < 0.0001). Additional prospective
studies exploring the interplay between CD8 T cells, EMT/
stromal elements and PD-L1 in larger patient cohorts will
be needed to confirm these findings.
PD-1/PD-L1 oncogenic signalling has also been
shown to play an important role in the regulation of EMT.
Atezolizumab, an anti‐PD‐L1 checkpoint inhibitor, was
shown to downregulate genes promoting cell migration,
invasion and metastasis in the human triple negative
breast cancer cell line MDA-MB-231 (50). In human
glioblastoma multiform (GBM) cells, PD-L1 significantly
altered cell growth, migration and invasion pathways by
upregulating N-cadherin, vimentin, Slug (an E-cadherin
transcriptional suppressor) and β-catenin (activates EMT
via the PI3K/Akt/mTOR pathway), and downregulating
E-cadherin gene expression (51). PD-L1 overexpression
promoted GBM development and invasion in orthotopic
GBM rat models. Following 48 h of IFN-γ treatment, we
also detected a significant increase in PD-L1 expression in
all thyroid cancer cell lines examined. This rise in PD-L1
was accompanied by phenotypic changes indicative of a
mesenchymal phenotype on imaging. This was confirmed
on Western blot, where a significant downregulation in
E-cadherin expression and upregulation of vimentin
levels was observed. Similar findings were reported by
Lo et al., in which IFNs enhanced RCC invasiveness by
increasing both Slug and ZEB1 gene expression (52).
IFN-γ induced PD-L1 upregulation may therefore be
involved in promoting EMT and may prove to be the
missing link in the treatment of mesenchymal cancers.
It is important to note that stromal cells have also been
identified as a key source of EMT-related gene expression
in colorectal, head and neck, and urothelial cancer (53,
54, 55). In a cohort of patients with metastatic urothelial
https://ec.bioscientifica.com
https://doi.org/10.1530/EC-20-0268

© 2020 The authors
Published by Bioscientifica Ltd

EMT, PD-L1 and CD8 as thyroid
cancer biomarkers

9:10

1038

cancer treated with nivolumab, patients with T-cell
infiltrated tumours and higher EMT/stroma-related gene
expression experienced lower response rates and shorter
progression-free and overall survival (53). Future research
is required to delineate the distinct roles of PD-L1 and
tumour-infiltrating stromal cells in activating EMT in
thyroid cancer. Collectively, these studies illuminate the
complex bidirectional regulation between EMT and PD-L1
signalling in cancer which ultimately leads to tumour
immune escape and invasion.
Interestingly, an integrated analysis of the genomic
and proteomic profiles from over 1000 tumours revealed
that additional targetable immune checkpoints are
present in cancers displaying an EMT phenotype,
including T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3), OX40 and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) (56). EMT may therefore
accelerate cancer growth and metastasis not only through
the direct reprogramming of the PD-1/PD-L1 axis, but also
via the modulation of several immune processes within
the tumour microenvironment. This finding highlights
the possibility of utilising EMT status as a supplementary
tool for the selection of patients who may benefit from
immune checkpoint inhibitors. Therapies targeting these
additional immune checkpoints may impede tumour
metastases and drug resistance mediated via EMT.
EMT status has also been shown to influence the degree
of response to PD-1/PD-L1 targeted immunotherapies.
Mammary tumour cells arising from epithelial carcinoma
cell lines were found to express lower levels of PD-L1
and elevated MHC-I, CD8 T cells and M1 (anti-tumour)
macrophages (57). In contrast, tumours from moremesenchymal carcinoma cell lines exhibited low levels of
MHC-I and an elevated expression EMT markers, PD-L1,
regulatory T cells, M2 (pro-tumour) macrophages and
exhausted CD8 T cells within their stroma. The more
mesenchymal carcinoma cells within a tumour were able to
safeguard their more epithelial counterparts from immune
attack, implicating the role of EMT in the regulation of the
tumour microenvironment. Moreover, epithelial tumours
were more susceptible to elimination by immunotherapy
than corresponding mesenchymal tumours. Therefore,
the implementation of EMT inhibitors as adjuvants to
immune checkpoint immunotherapies may enhance
responses in patients with mesenchymal tumours. In
patients with advanced melanoma, EMT signatures and
mesenchymal‐related genes were associated with innate
anti-PD-1 resistance (58). Additionally, patients with
bladder tumours characterised by an epithelial phenotype
had significantly higher response rates following
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treatment with atezolizumab therapy compared to those
harbouring a basal subtype (59). M7824, a novel first-inclass bifunctional anti-PD-L1 and TGF-β fusion protein,
was shown to revert TGF-β mediated mesenchymalisation
in NSCLC cells, as well as promote the activation of
CD8 T and NK cells, reduce tumour growth and extend
survival in animal models of colon and breast cancer. The
concurrent blockade of the PD-L1 and TGF-β pathways
elicited superior antitumour activity compared to either
monotherapy alone. These findings suggest that the
efficacy of anti-PD-1/PD-L1 checkpoint inhibitors may
be influenced by an individual’s EMT status. Additional
trials investigating the efficacy of combination strategies
comprised of EMT targeted agents and immune checkpoint
inhibitors will be needed to overcome patient resistance
and improve survival outcomes.
There were a number of limitations present in our
study, including its retrospective design, short median
follow-up, and small sample size. Moreover, it is
important to note that TMAs may not be representative
of the whole patient specimen. Prospective, longitudinal
studies with larger sample sizes will be needed to confirm
the predictive value of PD-L1, CD8 T-cells and an EMT
signature in thyroid cancer.
In conclusion, our results reveal the significant
prognostic capabilities of PD-L1 expression, CD8 T cell
status and EMT in PTC. Moreover, we provide a feasible
mechanism for the promotion of EMT in thyroid cells that is
mediated by PD-L1 expression in vitro. Patients exhibiting
an EMT phenotype and positive PD-L1 expression may
benefit from PD-1/PD-L1 targeted immunotherapy.
Additional research exploring the molecular mechanisms
underlying EMT regulation and its association with the
PD-1/PD-L1 axis will enhance our understanding of thyroid
carcinogenesis and provide alternative approaches for the
treatment of patients with aggressive disease.
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